In line with this, several recent studies have demonstrated that autophagy flux is increased upon KRAS or MAPK inhibition in PDAC or other KRAS or RAF-driven cancers, and that the combined inhibition of autophagy and the MAPK pathway exerts potent anti-tumor activity in a synergistic manner [119,120,121]. The gene discussed is KRAS; the disease is neoplasm.